Brain Disease
Conditions
Brief summary
The primary goal of this project is to study the feasibility of a brain-dedicated PET insert for an MR scanner for simultaneous acquisition of PET/MR images of human brains. The study will also allow us to compare the imaging performance of the investigator's brain-dedicated PET insert against a commercial whole-body permanently integrated PET/MRI system using a common radiopharmaceutical.
Detailed description
This study will enroll up to 40 participants. 1. 20 participants at Stanford injected with an FDA-approved PET tracer (e.g. amyloid, FDG, etc.), and 2. 20 participants from Stanford who have been pre-injected with a radiopharmaceutical for a study on another PET imaging system
Interventions
DIAGNOSTIC_TESTInjected radiotracer with PET Insert
1. Informed consent will be obtained before beginning any study procedures. 2. Participants will receive a small quantity of an FDA approved radiotracer. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed.
DIAGNOSTIC_TESTPre-injected group with PET insert
1. Informed consent will be obtained before beginning any study procedures. 2. Participants who have received radiotracer for another PET imaging system. The PET insert is placed within a 3T MRI scanner, where PET and MRI imaging will be completed.
Sponsors
Stanford University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Whole body radiation dose within the last year of less than 5000 mrem 2. Subjects intended for injected tracer studies (not associated with another study) must be willing/able to undergo injection of 6-12 mCi of either FDG or Neuraceq radiotracer. Both tracers are FDA approved 3. Subjects will be at least 21 years of age 4. Subject provides written informed consent 5. Subject is deemed healthy by the PI by via self-reported questionnaire
Exclusion criteria
1. For patients who will be receiving a tracer injection, no known allergy to the imaging agents 2. Participant has a history of or current diagnosis of cancer 3. Participant is pregnant or nursing 4. Metallic implants (contraindicated for MRI)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PETMR image | Up to 24 months | The key specific measurement is the resulting PET/MR image obtained from the single subject scan. |
Countries
United States
Contacts
Primary ContactPaul Newswanger
Outcome results
None listed